Chronic Oral Administration of CI-994: A Phase I Study
- 1 February 2001
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 19 (1) , 1-11
- https://doi.org/10.1023/a:1006489328324
Abstract
Objectives: CI-994 (N-acetyl dinaline, PD123654) is a novel oral agent active in a broad variety ofmurine and human tumor xenografts. While cytotoxic in theBrown Norway (BN) rat leukemia model,...Keywords
This publication has 9 references indexed in Scilit:
- Preclinical pharmacokinetic, antitumor and toxicity studies with CL-994 (N-acetyldinaline)Investigational New Drugs, 1997
- Preclinical toxicity of a new oral anticancer drug, CI-994 (Acetyldinaline), in rats and dogsInvestigational New Drugs, 1997
- Preclinical antitumor activity of CI-994Investigational New Drugs, 1996
- Role of a small molecular weight phosphoprotein in the mechanism of action of CI‐994 (N‐acetyldinaline)International Journal of Cancer, 1995
- New cytostatics—more activity and less toxicityCancer Treatment Reviews, 1990
- DINALINE - A NEW ORAL-DRUG AGAINST LEUKEMIA - PRECLINICAL STUDIES IN A RELEVANT RAT MODEL FOR HUMAN ACUTE MYELOCYTIC-LEUKEMIA (BNML)1988
- SYNTHESIS, TOXICITY, AND THERAPEUTIC EFFICACY OF 4-AMINO-N-(2'-AMINOPHENYL)-BENZAMIDE - A NEW COMPOUND PREFERENTIALLY ACTIVE IN SLOWLY GROWING TUMORS1985
- Effectiveness of P-aminobenzyol-O-phenylenediamine (Goe 1734) against mouse, rat, and human tumour cellsCancer Chemotherapy and Pharmacology, 1985
- INDUCTION AND CHEMOTHERAPEUTIC RESPONSE OF 2 TRANSPLANTABLE DUCTAL ADENOCARCINOMAS OF THE PANCREAS IN C57BL-6 MICE1984